COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    JNJ-63709178
Previous Study | Return to List | Next Study

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02715011
Recruitment Status : Recruiting
First Posted : March 22, 2016
Last Update Posted : April 24, 2020
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 29, 2020
Estimated Study Completion Date : October 4, 2022